SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group

BMC Medical Genetics

Volumn 12, Issue , 2011, Pages

  Santos, Paulo C J L ^a   Soares, Renata A G ^a   Nascimento, Raimundo M ^b   Machado Coelho, George L L ^b   Mill, José G ^c   Krieger, José E ^a   Pereira, Alexandre C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^c FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Amerindian; Myopathy; Pharmacogenetic; Rs4149056; Slco1b1; Statins

Indexed keywords

ORGANIC ANION TRANSPORTER 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC ANION TRANSPORTER; PRIMER DNA; SLCO1B1 PROTEIN, HUMAN;

ALLELE; ARTICLE; BRAZIL; DNA POLYMORPHISM; DNA SEQUENCE; ETHNICITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MYOPATHY; PHARMACOGENETICS; URBAN POPULATION; AMERICAN INDIAN; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; ETHNOLOGY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; MISSENSE MUTATION; MUSCLE DISEASE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSITION TEMPERATURE;

BRAZIL; DNA PRIMERS; GENE FREQUENCY; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDIANS, SOUTH AMERICAN; LINKAGE DISEQUILIBRIUM; MUSCULAR DISEASES; MUTATION, MISSENSE; ORGANIC ANION TRANSPORTERS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSITION TEMPERATURE;

EID: 80053928744     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-12-136     Document Type: Article

References (26)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278.
2. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis 210(2):337-343.
3. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97(8A):69C-76C.
4. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370(9601):1781-1790. 10.1016/S0140-6736(07)60716-8, 17559928.
5. Gotto AM. Statins, cardiovascular disease, and drug safety. Am J Cardiol 2006, 97(8A):3C-5C.
6. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006, 97(8A):52C-60C.
7. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 2007, 29(8):1761-1770. 10.1016/j.clinthera.2007.08.022, 17919557.
8. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2011,
9. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008, 359(8):789-799.
10. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54(17):1609-1616. 10.1016/j.jacc.2009.04.053, 19833260.
11. Niemi M, Pasanen MK, Neuvonen PJ. Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacol Rev 63(1):157-181.
12. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007, 82(6):726-733. 10.1038/sj.clpt.6100220, 17473846.
13. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006, 16(12):873-879. 10.1097/01.fpc.0000230416.82349.90, 17108811.
14. de Lima Santos PC, de Oliveira Alvim R, Ferreira NE, de Sa Cunha R, Krieger JE, Mill JG, Pereira AC. Ethnicity and arterial stiffness in Brazil. Am J Hypertens 24(3):278-284.
15. Santos PC, Pereira AC, Cancado RD, Schettert IT, Sobreira TJ, Oliveira PS, Hirata RD, Hirata MH, Figueiredo MS, Chiattone CS, et al. HFE gene mutations in patients with primary iron overload: is there a significant improvement in molecular diagnosis yield with HFE sequencing?. Blood Cells Mol Dis 45(4):302-307.
16. Makdisse M, Pereira Ada C, Brasil Dde P, Borges JL, Machado-Coelho GL, Krieger JE, Nascimento Neto RM, Chagas AC. Prevalence and risk factors associated with peripheral arterial disease in the Hearts of Brazil Project. Arq Bras Cardiol 2008, 91(6):370-382.
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16(3):1215. 10.1093/nar/16.3.1215, 334765, 3344216.
18. Alvim RO, Freitas SR, Ferreira NE, Santos PC, Cunha RS, Mill JG, Krieger JE, Pereira AC. APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population. Lipids Health Dis 9:128.
19. Santos PC, Soares RA, Krieger JE, Guerra-Shinohara EM, Pereira AC. Genotyping of the hemochromatosis HFE p.H63D and p.C282Y mutations by high-resolution melting with the Rotor-Gene 6000((R)) instrument. Clin Chem Lab Med 2011,
20. Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, Mill JG, Krieger JE, Pereira AC. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 12:13.
21. Mwinyi J, Kopke K, Schaefer M, Roots I, Gerloff T. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol 2008, 64(3):257-266. 10.1007/s00228-007-0409-y, 18185926.
22. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001, 276(38):35669-35675. 10.1074/jbc.M103792200, 11477075.
23. Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, Konig S, Ziesenitz V, Mikus G, Haefeli WE, Weiss J. Frequency of the SLCO1B1 388A > G and the 521T > C polymorphism in Tanzania genotyped by a new LightCycler(R)-based method. Eur J Clin Pharmacol 2011,
24. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Bailey DG, Michael Stein C, Kim RB. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 2007, 17(8):647-656. 10.1097/FPC.0b013e3280ef698f, 17622941.
25. Haiman CA, Stram DO. Exploring genetic susceptibility to cancer in diverse populations. Curr Opin Genet Dev 20(3):330-335.
26. Puccetti L, Ciani F, Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 211(1):28-29.